Catalog No.: PC-26956Not For Human Use, Lab Use Only.
Orforglipron hemicalcium hydrate (LY3502970, OWL-833) is a potent, selective, orally active non-peptide agonist of glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) with Ki of 1 nM.
Orforglipron hemicalcium hydrate (LY3502970, OWL-833) is a potent, selective, orally active non-peptide agonist of glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) with Ki of 1 nM. Orforglipron has low intrinsic efficacy for effector activation and negligible β-arrestin recruitment. Orforglipron is highly potent, displaying pharmacological bias toward the cAMP second messenger signalling pathway. Orforglipron exhibits full efficacy at reducing hyperglycaemia in experimental animals.
Physicochemical Properties
M.Wt
921.02
Formula
C48H48F2N10O5.1/2Ca.H2O
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one calcium salt hydrate (2:1:2)
References
1. Kawai T, et al. Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29959-29967.
2. Cong Z, et al. Nat Commun. 2021 Jun 18;12(1):3763.
3. Kyle W Sloop, et al. Sci Transl Med. 2024 Dec 18;16(778):eadp5765.
